公司資料
Regeneron Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- REGN
- 交易所:
- NASDAQ
- 產業:
- Antibody Drugs, Biopharma
- 所在地:
- United States
股票表現
805.93 USD (+0.30%)
收盤價
最後更新: 2026年8月17日
63.2B USD
市值
股價為何變動
As of Aug 17, 2026, REGN closed up 0.30% at $805.93. No new same-company headline was identified in the current news window.
公司概覽
Integrated Biopharmaceutical Company
Regeneron Pharmaceuticals discovers, develops, manufactures and commercializes medicines across ophthalmology, immunology, oncology, rare disease, cardiovascular medicine and other areas. Its internal technology platforms support a large clinical portfolio and multiple global collaborations.
Retinal Disease Franchise
EYLEA and EYLEA HD are anti-VEGF therapies used in retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema. EYLEA HD offers extended dosing intervals and anchors Regeneron’s ophthalmology business.
Dupixent Collaboration
Dupixent is an IL-4 receptor alpha antibody developed globally with Sanofi across type 2 inflammatory diseases. Its indications span dermatologic, respiratory and allergic conditions, including recent expansions into pediatric chronic spontaneous urticaria and allergic fungal rhinosinusitis.
Oncology Pipeline
Regeneron commercializes the PD-1 antibody Libtayo and is developing fianlimab, a LAG-3 antibody, with cemiplimab in metastatic and adjuvant melanoma. The company’s oncology strategy combines proprietary antibodies across complementary immune pathways.
Rare-Disease Medicines
Otarmeni is an approved AAV gene therapy for OTOF-related severe-to-profound hearing loss. Garetosmab, an Activin A antibody, is under regulatory review for fibrodysplasia ossificans progressiva, while cemdisiran is an siRNA therapy submitted for myasthenia gravis.
Cardiovascular and Metabolic Programs
REGN7508 and REGN9933 are Factor XI antibodies in Phase 3 development for thrombosis prevention. Mibavademab is a leptin-receptor agonist antibody in Phase 3 testing for monogenic obesity.
未來催化劑
- FDA decisions on EYLEA HD prefilled-syringe manufacturing applications anticipated in the second quarter of 2026.
- Phase 3 first-line metastatic-melanoma results for fianlimab plus cemiplimab expected in the second quarter of 2026.
- Second interim or final analysis of the adjuvant-melanoma fianlimab study expected in the second half of 2026.
- FDA action on the garetosmab BLA for FOP targeted for August 2026.
- FDA filing acceptance for cemdisiran anticipated in the second quarter of 2026, with a decision expected in the fourth quarter.
- Additional Phase 3 Factor XI antibody studies planned later in 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。